Contribute Try STAT+ Today

Last fall, the governments of India and South Africa asked the World Trade Organization to waive some provisions in a trade agreement governing intellectual property rights so that Covid-19 medical products can be more easily accessed, especially by low-income countries. Their argument is that, unless a waiver is issued, diagnostics, medicines, and vaccines will not be available promptly in sufficient quantities and at affordable prices to meet global demand. But the effort has stalled as some wealthy nations have balked at the idea. The U.S. Chamber of Commerce says the proposal is “misguided and a distraction from the real work of reinforcing supply chains.” For its part, the pharmaceutical industry insists that intellectual property is not a barrier to access. Meanwhile, the incoming WTO director-general last week hinted at a “third way” that could involve licensing agreements. We spoke with Mustaqeem De Gama, the counselor at the South African Mission in Geneva, about the rationale and prospects for the proposal, which will be discussed at yet another WTO meeting next week. This is an edited version of our conversation. 

So let’s start at the beginning. Why did you push this proposal?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.